Literature DB >> 35294642

The role of MRI in prostate cancer: current and future directions.

Maria Clara Fernandes1, Onur Yildirim1, Sungmin Woo2, Hebert Alberto Vargas1, Hedvig Hricak1.   

Abstract

There has been an increasing role of magnetic resonance imaging (MRI) in the management of prostate cancer. MRI already plays an essential role in the detection and staging, with the introduction of functional MRI sequences. Recent advancements in radiomics and artificial intelligence are being tested to potentially improve detection, assessment of aggressiveness, and provide usefulness as a prognostic marker. MRI can improve pretreatment risk stratification and therefore selection of and follow-up of patients for active surveillance. MRI can also assist in guiding targeted biopsy, treatment planning and follow-up after treatment to assess local recurrence. MRI has gained importance in the evaluation of metastatic disease with emerging technology including whole-body MRI and integrated positron emission tomography/MRI, allowing for not only better detection but also quantification. The main goal of this article is to review the most recent advances on MRI in prostate cancer and provide insights into its potential clinical roles from the radiologist's perspective. In each of the sections, specific roles of MRI tailored to each clinical setting are discussed along with its strengths and weakness including already established material related to MRI and the introduction of recent advancements on MRI.
© 2022. The Author(s), under exclusive licence to European Society for Magnetic Resonance in Medicine and Biology (ESMRMB).

Entities:  

Keywords:  Active surveillance; Biochemical recurrence; Diffusion-weighted imaging; Dynamic contrast-enhanced MRI; MRI; Metastasis; Prostate cancer; Staging

Mesh:

Year:  2022        PMID: 35294642      PMCID: PMC9378354          DOI: 10.1007/s10334-022-01006-6

Source DB:  PubMed          Journal:  MAGMA        ISSN: 0968-5243            Impact factor:   2.533


  156 in total

1.  Extracapsular extension in prostate cancer: added value of diffusion-weighted MRI in patients with equivocal findings on T2-weighted imaging.

Authors:  Sungmin Woo; Jeong Yeon Cho; Sang Youn Kim; Seung Hyup Kim
Journal:  AJR Am J Roentgenol       Date:  2015-02       Impact factor: 3.959

2.  Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study.

Authors:  Peter Ström; Kimmo Kartasalo; Henrik Olsson; Leslie Solorzano; Brett Delahunt; Daniel M Berney; David G Bostwick; Andrew J Evans; David J Grignon; Peter A Humphrey; Kenneth A Iczkowski; James G Kench; Glen Kristiansen; Theodorus H van der Kwast; Katia R M Leite; Jesse K McKenney; Jon Oxley; Chin-Chen Pan; Hemamali Samaratunga; John R Srigley; Hiroyuki Takahashi; Toyonori Tsuzuki; Murali Varma; Ming Zhou; Johan Lindberg; Cecilia Lindskog; Pekka Ruusuvuori; Carolina Wählby; Henrik Grönberg; Mattias Rantalainen; Lars Egevad; Martin Eklund
Journal:  Lancet Oncol       Date:  2020-01-08       Impact factor: 41.316

3.  Mass-like peripheral zone enhancement on CT is predictive of higher-grade (Gleason 4 + 3 and higher) prostate cancer.

Authors:  D I Glazer; M S Davenport; S Khalatbari; R H Cohan; J H Ellis; E M Caoili; E B Stein; J C Childress; W R Masch; J M Brown; B J Mollard; J S Montgomery; G S Palapattu; I R Francis
Journal:  Abdom Imaging       Date:  2015-03

4.  Comparing deep learning-based auto-segmentation of organs at risk and clinical target volumes to expert inter-observer variability in radiotherapy planning.

Authors:  Jordan Wong; Allan Fong; Nevin McVicar; Sally Smith; Joshua Giambattista; Derek Wells; Carter Kolbeck; Jonathan Giambattista; Lovedeep Gondara; Abraham Alexander
Journal:  Radiother Oncol       Date:  2019-12-05       Impact factor: 6.280

5.  Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps--initial observations.

Authors:  Carolin Reischauer; Johannes M Froehlich; Dow-Mu Koh; Nicole Graf; Christian Padevit; Hubert John; Christoph A Binkert; Peter Boesiger; Andreas Gutzeit
Journal:  Radiology       Date:  2010-09-09       Impact factor: 11.105

6.  Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T.

Authors:  Thiele Kobus; Pieter C Vos; Thomas Hambrock; Maarten De Rooij; Christina A Hulsbergen-Van de Kaa; Jelle O Barentsz; Arend Heerschap; Tom W J Scheenen
Journal:  Radiology       Date:  2012-07-27       Impact factor: 11.105

Review 7.  Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy.

Authors:  L M Wu; J-R Xu; H Y Gu; J Hua; J Zhu; J Chen; W Zhang; J Hu
Journal:  Clin Oncol (R Coll Radiol)       Date:  2013-01-11       Impact factor: 4.126

8.  MRI-Targeted or Standard Biopsy in Prostate Cancer Screening.

Authors:  Martin Eklund; Fredrik Jäderling; Andrea Discacciati; Martin Bergman; Magnus Annerstedt; Markus Aly; Axel Glaessgen; Stefan Carlsson; Henrik Grönberg; Tobias Nordström
Journal:  N Engl J Med       Date:  2021-07-09       Impact factor: 91.245

9.  Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.

Authors:  Michael S Hofman; Nathan Lawrentschuk; Roslyn J Francis; Colin Tang; Ian Vela; Paul Thomas; Natalie Rutherford; Jarad M Martin; Mark Frydenberg; Ramdave Shakher; Lih-Ming Wong; Kim Taubman; Sze Ting Lee; Edward Hsiao; Paul Roach; Michelle Nottage; Ian Kirkwood; Dickon Hayne; Emma Link; Petra Marusic; Anetta Matera; Alan Herschtal; Amir Iravani; Rodney J Hicks; Scott Williams; Declan G Murphy
Journal:  Lancet       Date:  2020-03-22       Impact factor: 79.321

10.  Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force.

Authors:  Caroline M Moore; Francesco Giganti; Peter Albertsen; Clare Allen; Chris Bangma; Alberto Briganti; Peter Carroll; Masoom Haider; Veeru Kasivisvanathan; Alex Kirkham; Laurence Klotz; Adil Ouzzane; Anwar R Padhani; Valeria Panebianco; Peter Pinto; Philippe Puech; Antti Rannikko; Raphaele Renard-Penna; Karim Touijer; Baris Turkbey; Heinrik van Poppel; Riccardo Valdagni; Jochen Walz; Ivo Schoots
Journal:  Eur Urol       Date:  2016-06-24       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.